Chemotalk Newsletter

The Chemotalk Newsletter is published once a month, and contains an overview of news stories that relate to chemotherapy treatment for cancer, multiple sclerosis, rheumatoid arthritis, or for anyone who has received an organ transplant.

Sign up to receive the monthly
Chemotalk Newsletter, and bulletins
about important chemotherapy breakthroughs.
E-mail address:
Subscribe Unsubscribe
 
Chemotalk Newsletter, Vol. 112: August 1, 2017

CAR-T CELL THERAPY GIVEN GREEN LIGHT BY ODAC FOR B-CELL ACUTE LYMPHOBASTIC LEUKEMIA

By John Schieszer

    It looks like 2017 will be a transformative year for CAR-T therapy. The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of CTL019 (tisagenlecleucel) on July 12, 2017 for the treatment of relapsed or refractory pediatric and young adult patients with B-CELL ACUTE LYMHOBLASTIC LEUKEMIA (ALL).

    Tisagenlecleucel is an investigational chimeric antigen receptor (CAR) T cell therapy by Novartis. The advisory committee hearing was the last major regulatory milestone before the agency decides in September whether to approve the treatment, which would make this the first-ever commercially approved CAR-T cell therapy. The committee¹s unanimous positive vote bodes well for this gene therapy approach.

    Effective treatment options for patients with relapsed/refractory ALL are limited. In pediatric and young adult patients with B-cell ALL who relapse or are refractory to treatment, the survival rates are very low. "We know firsthand from treating children and young adults with relapsed/refractory B-cell ALL that they desperately need innovative medicines that provide a new approach to managing this aggressive disease," said Stephan Grupp, MD, PhD, Professor of Pediatrics at the Perelman School of Medicine at Pennsylvania University and Director of the Cancer Immunotherapy Frontier Program, both in Philadelphia, Pennsylvania.

    CTL019 was first developed by the University of Pennsylvania and uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular responses. This approach in clinical studies has been associated with long-lasting remissions in relapsed and treatment refractory patients.

    CAR-T is manufactured for each individual patient using their own cells. During the treatment process, T cells are drawn from a patient's blood and reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other B-cells.

Read more...

Vol 105: January, 2017

Vol 106: February, 2017

Vol 109: May, 2017

Vol 110: June, 2017

Vol 111: July, 2017

Vol 112: August, 2017

Vol 93: January, 2016

Vol. 94: February, 2016

Vol. 95: March, 2016

Vol. 96: April, 2016

Vol. 97: May, 2016

Vol. 98: June, 2016

Vol. 99: July, 2016

Vol. 100: August, 2016

Vol. 101: September, 2016

Vol. 102: October, 2016

Vol. 103: November, 2016

Vol. 104: December, 2016

Vol 81: January, 2015

Vol 82: February, 2015

Vol 83: March, 2015

Vol 84: April, 2015

Vol 85: May, 2015

Vol 86: June, 2015

Vol 87: July, 2015

Vol 88: August, 2015

Vol 89: September, 2015

Vol 90: October, 2015

Vol 91: November, 2015

Vol 92: December, 2015

Vol. 69: January, 2014

Vol 70: February, 2014

Vol 71: March, 2014

Vol 72: April, 2014

Vol 73: May, 2014

Vol 74: June, 2014

Vol 75: July, 2014

Vol 76: August, 2014

Vol 77: September, 2014

Vol 78: October, 2014

Vol 79: November, 2014

Vol 80: December, 2014

Vol 57: January, 2013

Vol 58: February, 2013

Vol 59: March, 2013

Vol. 60: April, 2013

Vol. 61: May, 2013

Vol. 62: June, 2013

Vol. 63: July, 2013

Vol. 64: August, 2013

Vol. 65: September, 2013

Vol. 66: October, 2013

Vol. 67: November, 2013

Vol. 68: December, 2013

Vol 56: December, 2012

Vol 55: November, 2012

Vol 54: October, 2012

Vol 53: September, 2012

Vol 52: August, 2012

Vol 51: July, 2012

Vol 50: June, 2012

Vol 49: May, 2012

Vol 48: April, 2012

Vol 47: March, 2012

Vol 46: February, 2012

Vol 45: January, 2012

Vol 44: December, 2011

Vol 43: November, 2011

Vol 42: October, 2011

Vol 41: September, 2011

Vol 40: August, 2011

Vol 39: July, 2011

Vol 38: June, 2011

Vol 37: May 1, 2011

Vol 36: April 1, 2011

Vol 35: March 1, 2011

Vol 34: February 1, 2011

Vol 33: January 1, 2011

Vol 32: December 1, 2010

Vol 31: November 1, 2010

Vol 30: October 1, 2010

Vol 29: September, 2010

Vol 28: August, 2010

Vol 27: July, 2010

Vol 26: June, 2010

Vol. 25: May, 2010

Vol. 24: April, 2010

Vol. 23: March, 2010

Vol. 22: February, 2010

Vol. 21: January, 2010

Vol. 20: December, 2009

Vol. 19: November, 2009

Vol. 18: October, 2009

Vol. 17: September, 2009

Vol. 16: August, 2009

Vol. 15: July, 2009

Vol. 13: June, 2009

Vol. 12: May, 2009

Vol. 11: April, 2009

Vol. 10: March, 2009

Vol. 9: February, 2009

Vol. 8: January, 2009

Vol. 7: December, 2008

Vol. 6: November, 2008

Vol. 5: October, 2008

Vol. 4: September, 2008

Vol. 3: August, 2008

Vol. 2:  July 1, 2008

Vol. 1:  June 1, 2008

 

 


Home | About Elaine | About the Book | Mission | ChemoTalk.com | Chemotalk Newsletter | Media Room |
Chemo Coaching | Speaking Engagements | Blog | Links | Contact